Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$10.01 USD
-0.25 (-2.44%)
Updated May 24, 2024 04:00 PM ET
After-Market: $10.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Iovance Biotherapeutics, Inc. [IOVA]
Reports for Purchase
Showing records 61 - 80 ( 180 total )
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Registrational Cohort Results Reinforce Lifileucel BLA Submission in August For Advanced Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Anticipated BLA Submission Rapidly Approaches Bolstered by Cash Balance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Finally! Regulatory Endgame Back in Play; BLA by August; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Clinical Programs Advance as FDA Guidance Is Forthcoming; BLA Submission on Track for 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Raring to Go; iCTC Facility Is a Testament to TIL''s Commercial Readiness
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TILs Impress Across Assorted Solid Tumor Types at SITC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; FDA Potency Approval Is Palpable; SITC Update Important; Adjusting Price Target to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department